- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Interventions
- Psychoeducational skills training intervention
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 2,117
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease
- Interventions
- [18F] MNI-558
- Drug
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer's Disease
- Interventions
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Magnetic Resonance Imaging, Alzheimer's Disease, Dementia, Adult Children, Risk
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Interventions
- AG10, Placebo
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Interventions
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Device · Behavioral
- Lead sponsor
- Boston University
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- Jeff Burns, MD
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Interventions
- LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
- Conditions
- Alzheimer's Disease, Huntington Disease
- Interventions
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2, Dimebon MR3, Dimebon MR4
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- MCI, Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Device
- Lead sponsor
- iPACES LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Clifton Park, New York
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- E2814, Lecanemab, Matching Placebo (E2814)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Dementia, Mild, Depression
- Interventions
- Decision aid
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alzheimer Disease
- Interventions
- Mevidalen, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Carlsbad, California + 40 more
- Conditions
- Alzheimers Disease Related Dementias
- Interventions
- Health App Recommendation Tool (HART)
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 856 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Early Alzheimers Disease
- Interventions
- buntanetap/posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 78
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
- Conditions
- Alzheimer Disease
- Interventions
- 18F-Fluselenamyl
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tauopathies
- Interventions
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 185
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
- Interventions
- Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
- Device
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- PF-03654746, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Wichita, Kansas
- Conditions
- Dementia, Alzheimer Type
- Interventions
- Xanamem™, Placebo (for Xanamem™)
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Poway, California + 11 more